{
    "clinical_study": {
        "@rank": "41707", 
        "arm_group": [
            {
                "arm_group_label": "JZoloft", 
                "arm_group_type": "Active Comparator", 
                "description": "Oral tablet of sertraline hydrochloride (Japanese commercial tablet: JZoloft \u00ae tablet) 50 mg as a single oral dose under fasted conditions"
            }, 
            {
                "arm_group_label": "ODT without water", 
                "arm_group_type": "Experimental", 
                "description": "sertraline ODT 50 mg without water as a single oral dose under fasted conditions"
            }, 
            {
                "arm_group_label": "ODT with water", 
                "arm_group_type": "Experimental", 
                "description": "sertraline ODT 50 mg with water as a single oral dose under fasted conditions"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the bioequivalence of Zoloft ODT 50 mg with and\n      without water to Japanese commercial oral tablet of JZoloft 50 mg under fasting condition\n      with water in Healthy Japanese Subjects"
        }, 
        "brief_title": "Bioequivalence Of Zoloft ODT To Jzoloft In Healthy Japanese Subjects", 
        "completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy Japanese subjects between the ages of 20 and 55 years.\n\n          -  Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110\n             lbs).\n\n        Exclusion Criteria:\n\n          -  Significant psychiatric disorder, recurrent episodes of severe depression, or\n             subjects with serious suicidal risk per criteria.\n\n          -  Pregnant or nursing females; females of childbearing potential who are unwilling or\n             unable to use an acceptable method of nonhormonal contraception as outlined in this\n             protocol from at least 14 days prior to the first dose of study medication and for 28\n             days after the last dose of study medication."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 18, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01699724", 
            "org_study_id": "A0501098"
        }, 
        "intervention": [
            {
                "arm_group_label": "JZoloft", 
                "description": "50 mg tablet on Day 1 of each period", 
                "intervention_name": "JZoloft", 
                "intervention_type": "Drug", 
                "other_name": "sertraline hydrochloride"
            }, 
            {
                "arm_group_label": "ODT without water", 
                "description": "50 mg tablet on Day 1 of each period", 
                "intervention_name": "sertraline ODT", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "ODT with water", 
                "description": "50 mg tablet on Day 1 of each period", 
                "intervention_name": "sertraline ODT", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Sertraline"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "JZoloft", 
            "Sertraline hydrochloride", 
            "ODT", 
            "bioequivalence"
        ], 
        "lastchanged_date": "October 31, 2012", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A0501098&StudyName=Bioequivalence%20Of%20Zoloft%20ODT%20To%20Jzoloft%20In%20Healthy%20Japanese%20Subjects"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Hachioji-shi", 
                    "country": "Japan", 
                    "state": "Tokyo"
                }, 
                "name": "Pfizer Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "3", 
        "official_title": "Phase 1, Open-Label, Randomized, Single-Dose, 3-Way Crossover Assessing Bioequivalence Of Zoloft ODT 50 Mg Under Fasting Condition With And Without Water To Jzoloft Tablet 50 Mg Under Fasting Condition With Water In Healthy Japanese Subjects", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "AUC from zero to the last sampling point (AUCt) of sertraline after dose of sertraline ODT 50 mg without water to Japanese commercial oral tablet of JZoloft 50 mg under fasted conditions", 
                "safety_issue": "No", 
                "time_frame": "0, 1, 2, 4, 6, 7, 8, 10, 12, 24, 36, 48 and 72 hours post-dose"
            }, 
            {
                "measure": "Maximum plasma concentration (Cmax) of sertraline after dose of sertraline ODT 50 mg without water to Japanese commercial oral tablet of JZoloft 50 mg under fasted conditions", 
                "safety_issue": "No", 
                "time_frame": "0, 1, 2, 4, 6, 7, 8, 10, 12, 24, 36, 48 and 72 hours post-dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01699724"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Cmax and AUCt of sertraline after dose of sertraline ODT 50 mg with water to Japanese commercial oral tablet of JZoloft 50 mg under fasted conditions", 
                "safety_issue": "No", 
                "time_frame": "0, 1, 2, 4, 6, 7, 8, 10, 12, 24, 36, 48 and 72 hours post-dose"
            }, 
            {
                "measure": "Time of maximum plasma concentration of sertraline ODT 50 mg with water to Japanese commercial oral tablet of JZoloft 50 mg under fasted conditions", 
                "safety_issue": "No", 
                "time_frame": "0, 1, 2, 4, 6, 7, 8, 10, 12, 24, 36, 48 and 72 hours post-dose"
            }, 
            {
                "measure": "AUC from zero to infinity or last measurable concentration of sertraline after dose of sertraline ODT 50 mg with and without water to Japanese commercial oral tablet of JZoloft 50 mg under fasted conditions", 
                "safety_issue": "No", 
                "time_frame": "0, 1, 2, 4, 6, 7, 8, 10, 12, 24, 36, 48 and 72 hours post-dose"
            }, 
            {
                "measure": "Terminal elimination rate constant (kel), half-life (t\u00bd) and mean residence time (MRT) of sertraline ODT 50 mg with and without water to Japanese commercial oral tablet of JZoloft 50 mg under fasted conditions", 
                "safety_issue": "No", 
                "time_frame": "0, 1, 2, 4, 6, 7, 8, 10, 12, 24, 36, 48 and 72 hours post-dose"
            }, 
            {
                "measure": "Safety laboratory tests, vital signs, and adverse events (AEs)", 
                "safety_issue": "Yes", 
                "time_frame": "From Periods 1 to 3"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}